Intech Investment Management LLC Purchases Shares of 62,120 ADMA Biologics, Inc. (NASDAQ:ADMA)

Intech Investment Management LLC acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 62,120 shares of the biotechnology company's stock, valued at approximately $1,242,000.

Other hedge funds also recently added to or reduced their stakes in the company. USA Financial Formulas boosted its position in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after acquiring an additional 539 shares in the last quarter. Vontobel Holding Ltd. boosted its position in ADMA Biologics by 7.0% during the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock valued at $273,000 after purchasing an additional 888 shares in the last quarter. Hollencrest Capital Management purchased a new position in ADMA Biologics in the third quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. grew its stake in ADMA Biologics by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock valued at $163,000 after purchasing an additional 1,509 shares during the last quarter. Finally, Chartwell Investment Partners LLC raised its holdings in ADMA Biologics by 0.8% in the third quarter. Chartwell Investment Partners LLC now owns 249,779 shares of the biotechnology company's stock worth $4,993,000 after purchasing an additional 2,038 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA traded up $0.01 during mid-day trading on Wednesday, reaching $21.83. The company's stock had a trading volume of 1,940,312 shares, compared to its average volume of 3,621,177. The stock has a 50-day moving average of $18.98 and a two-hundred day moving average of $15.14. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a market capitalization of $5.16 billion, a P/E ratio of 77.93 and a beta of 0.64. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter last year, the business posted $0.01 earnings per share. On average, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Raymond James raised their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

Insider Buying and Selling

In other ADMA Biologics news, Director Jerrold B. Grossman sold 136,861 shares of ADMA Biologics stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the completion of the sale, the director now directly owns 467,305 shares in the company, valued at $8,070,357.35. This trade represents a 22.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the company's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the transaction, the chief operating officer now owns 449,088 shares in the company, valued at approximately $7,589,587.20. This represents a 5.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 185,011 shares of company stock worth $3,255,204. Insiders own 3.70% of the company's stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.